Clinical Research Directory

Inclusion Criteria: * Patients with metastatic hormone sensitive prostate cancer (mHSPC) * Patients must have bone metastases according to the most recent imaging (Bone scan, CT, MRI and/or PET) * Patients must be treated with androgen deprivation therapy (ADT) (orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist treatment) started \< 12 months ago. Additional treatment in the mHSPC setting, i.e., radiotherapy (RT) of the prostate, novel hormone agents (NHA) and/or docetaxel is permitted * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status score \<2 * Patients must be able to speak and read Danish and provide a signed informed consent form * Patients must be ambulatory without walking aids Exclusion Criteria: * Patients with any physical condition that interferes with the performance of physical exercise training * Patients with presence of any musculoskeletal, cardiovascular, or neurologic conditions that may prevent patients from exercising * Patients with bone pain requiring opioids * Patients with planned or prior palliative radiation therapy to the bone * Patients with major surgery within the past 6 months HIPimmune: all patients included in HIP are eligible for HIPimmune